TEM · Tempus AI, Inc.
$52.10
-2.19 (-4.03%)
At close · Aug 14
Market Cap
$9.85B
Shares
180.43M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$52.10
Open$53.90
Day$51.76–54.04
52W close$41.55–103.25
Avg vol 30d4.8M
Short int33.2M · 18.4% float · 5.9d
Short vol45%
Last earningsJul 30, 2026
DataJun 2024–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 25, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
+1%
above
RSI (14)
53
neutral
MACD trend
Positive
52-week position
17%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−9%
trailing
YTD return
−12%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $52 › 200d $57 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +124 funds added
Insider flow
Distributing
Net -$2.7M over 90 days · 100% sells
Short interest
Rising
18.42% of float · ▲ +9.5% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
490 holders — near 2-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
+83%
Y/Y
EPS growth
+77%
Y/Y
Free cash flow
$-239.1M
Balance sheet
$604.8M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Full year 2026 revenue
· full year 2026
$1.6B – $1.61B
Adjusted EBITDA
· full year 2026
Non-GAAP
$65M
Prior guidance
period ended
· from the Earnings Call filed Jun 30, 2025
Full year 2025 revenue
· full year 2025
$1.26B
Adjusted EBITDA
· full year 2025
$5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $52 › 200d $57 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +124 funds added
Insider flow
Distributing
Net -$2.7M over 90 days · 100% sells
Short interest
Rising
18.42% of float · ▲ +9.5% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
490 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $42
Now $52 · 17%
Range high $103
vs 200-day avg -9%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Data Licensing & Modeling (Insights) revenue growth | 36% | Q2 2026 | — |
| Hereditary revenue growth | 5% | Q2 2026 | — |
| Molecular residual disease (MRD) volume | 9,000 | Q2 2026 | — |
|
|
|||
| Oncology volume growth | 31% | Q2 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | -$2.8M | the first quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net loss -125.92M
-3.87M Interest income
+14.34M Interest expense
+7.43M Depreciation
+18.75M Amortization
-62K Benefit from income taxes
+3.09M Losses from equity method investments
+31.14M Fair value changes
+52.71M Stock-based compensation expense
+3.56M Employer payroll tax related to stock-based compensation
-4K Acquisition related expenses
-3.99M Amortization of technology license
= Adjusted EBITDA -2.83M
|
|||
| Hereditary volume growth | 29% | Full Year 2025 | — |
| Net Revenue Retention | 126% | Q4 FY2025 | — |
| Total Remaining Contract Value | 1.1B | Q4 FY2025 | — |
| Total Contract Value (TCV) | 1.1B | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TEM
this stock
Tempus AI, Inc.
|
$9.85B | -11.8% | +83.4% | — | 18.4% |
|
VEEV
Veeva Systems Inc
|
$39.23B | +9.2% | +28.1% | 42.8 | 4.5% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.41B | -18.8% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.21B | +64.8% | +28.2% | 37.4 | 4.2% |
|
HQY
Healthequity, Inc.
|
$8.76B | +14.3% | +28.7% | 39.2 | 5.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TEM | +0.1% | -0.7% | -9.1% | +18.8% | -11.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.3% | -5.2% | -22.8% | +14.8% | -25.6% |
Key facts
CIK
1717115
CUSIP
88023B103
13F (30d)
459 filings
455 filers
Visit website
Investor relations